News

Gene expression analyses by real-time PCR (or qPCR) are currently used to measure drug effects or to identify subpopulations of patients mostly likely to benefit from a specific therapy. The success of a qPCR experiment relies on the combination of a unique triptych: the selection of relevant and regulated target genes, the identification of a couple or more stable and experiment-specific reference genes, also called housekeeping genes, and robust statistical analyses. Thus, if some consider the target genes as the Kings of their experiment, the reference genes are the Queens of the equation!

ACOBIOM is involved in a national collaborative clinical research program: OncoSNIPE®, whose objectives are to identify early and late markers of resistance to 1st line treatments in locally advanced or metastatic triple negative breast cancer, non-small-cell lung cancer and pancreatic ductal adenocarcinoma. In this project, the scientific team of the company develops an optimized pipeline of bioinformatics and biostatistics tools to perform in routine, in blood and tissue, DNA and RNA analyses from hundreds of sequencing experiments.
These types of approaches associated with standardized protocols are applied to clinical trials with the objective of the identification of prognostic biomarkers associated with new therapies.

On behalf of a European consortium, ACOBIOM performed omics data analysis to strengthen the biological and clinical evaluation of an innovative medical device that aims to reduce chronic gum inflammation and restore oral soft tissue health. These analyses of tissue inflammasome are a recognition of the company’s technology platform, its technical expertise in the identification and selection of a panel of relevant RNA biomarkers related to inflammation, as well as in the biological and statistical analysis of transcriptomic data.

Acobiom has just contributed its genomic expertise to a biotech company that is developing a drug against endometriosis, which affects about 10% of women during their menorrhea.

Since its foundation, ACOBIOM provides omics services based on sequencing and PCR technologies associated with a range of selected and dedicated bioinformatics tools and biostatistical algorithms in order to process and analyze genomics and transcriptomics data.
The objective: identifying, selecting and/or validating DNA or RNA biomarkers in correlation with biological questions (pathology detection, drug effects, biomarker identification, patient stratification…), whatever the tissue or organ.

The MeDIAGSTOLE project aims to develop diagnostic and prognostic tools for left ventricular heart
failure with preserved ejection fraction (HF/pEF), a pathology that is difficult to diagnose and clinically
manage in the absence of targeted treatment. In this context, the University Hospital of Montpellier
and ACOBIOM decided to collaborate in order to identify biomarkers associated with this pathology,
and thus to participate in the implementation of personalized medicine for patients suffering from
this type of heart failure (HF/pEF).

Unlike DNA, which is constituted at birth and changes little over the course of Life, RNA is constantly evolving, reflecting the general state of health of the cell, organ and organism to which it belongs. RNA analysis (or gene expression analysis) is a particularly relevant approach to identify the biological markers (biomarkers) or the molecular targets associated to a biological process, a physio-pathological event, as the onset or the progression of a disease, the effects or the response to a drug or a treatment. RNA-Seq, a high throughput approach to perform RNA analysis by sequencing, become the standard technology to identify transcripts in cells and to quantify the associated expressed genes.

GEMCITEST® is a molecular diagnostic that uses blood samples to identify pancreatic cancer patients most likely to benefit from first-line gemcitabine treatment.

The abstract presented at the 2021 ASCO Annual Conference is a study synthesis of the clinical performance of the CE-IVD molecular test to assess the gemcitabine response in advanced pancreatic cancer.

Within the framework of the SME Instrument-Phase 1 call for projects, Europe provided a financial support to ACOBIOM in order to evaluate the costs of the current management of pancreatic cancer in France. This study will confirm the sale forecasts of the GemciTest in France and in Europe.